A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (NCT04543617)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
Who can join: Review the eligibility criteria below.
Location: Florida Cancer Specialists - Fort Myers (Broadway) — Fort Myers, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (167 Sites)
Showing the first 25 of 167 sites.
- Florida Cancer Specialists - Fort Myers (Broadway) — Fort Myers, Florida
- Cancer Center of Kansas — Wichita, Kansas
- Great Lakes Cancer Center — Williamsville, New York
- Instituto de Investigaciones Metabolicas (Idim) — Buenos Aires,
- Fundacion Favaloro — Buenos Aires,
- Centro Oncologico Riojano Integral (CORI) — La Rioja,
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Austin Health — Heidelberg, Victoria
- St John of God Hospital — Subiaco, Western Australia
- Tiroler Landeskrankenanstalten Ges.M.B.H. — Innsbruck,
- Klinikum Klagenfurt am Wörthersee — Klagenfurt,
- Ordensklinikum Linz Barmherzige Schwestern — Linz,
- AKH - Medizinische Universität Wien — Vienna,
- UZ Antwerpen — Edegem,
- UZ Leuven Gasthuisberg — Leuven,
- CHU de Liège (Sart Tilman) — Liège,
- Anyang Tumor Hosptial — Anyang,
- Cancer Hospital Chinese Academy of Medical Sciences. — Beijing,
- Affiliated Hospital of Bengbu Medical College — Bengbu,
- Hunan Cancer Hospital — Changsha,
- Heping Hospital Affiliated to Changzhi Medical College — Changzhi,
- Changzhou Cancer hospital — Changzhou,
- Sichuan Provincial Cancer Hospital — Chengdu,
- West China Hospital, Sichuan University — Chengdu,
- Chongqing Cancer Hospital — Chongqing,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Esophageal Squamous Cell Carcinoma
- Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC — Atlanta, Georgia
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) — Pittsburgh, Pennsylvania
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) — Tucson, Arizona
- Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer — Montreal, Quebec
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — Denver, Colorado
Explore by condition: All Esophageal Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.